Search results for "Bone Density"

showing 10 items of 339 documents

Immobilization of BMP‐2, BMP‐7 and alendronic acid on titanium surfaces: Adhesion, proliferation and differentiation of bone marrow‐derived stem cells

2019

This study analyzed the influence of titanium (TiO2 ) surface modifications with two osteogenic proteins (BMP-2, BMP-7) and an anti-osteoclastic drug (alendronic acid [AA]) on sandblasted/acid-etched (SLA) and plain TiO2 (PT) on cell adhesion, proliferation and differentiation (alkaline phosphatase [AP] and osteocalcin [OC]) of bone-marrow derived stem cells (BMSCs) after 1, 3 and 7 days in-vitro. Initially, AA surfaces showed the highest cell number and surface coverage. At day 3 and 7, BMP and AA-modified surfaces exhibited a significantly enhanced cell growth. For proliferation, at days 3 and 7, an enhancement on BMP-2, BMP-7 and AA-surfaces was seen. At day 7, SLA also showed a higher p…

Materials scienceSurface PropertiesBone Morphogenetic Protein 70206 medical engineeringBiomedical EngineeringBone Morphogenetic Protein 2Biocompatible MaterialsBone Marrow Cells02 engineering and technologyBone morphogenetic protein 2BiomaterialsOsteogenesisCell AdhesionmedicineHumansCell adhesionCells CulturedCell ProliferationTitaniumAlendronateBone Density Conservation AgentsbiologyCell growthStem CellsAlendronic acidfungiMetals and AlloysCell DifferentiationAdhesion021001 nanoscience & nanotechnology020601 biomedical engineeringMolecular biologyImmobilized Proteinsmedicine.anatomical_structureembryonic structuresCeramics and CompositesOsteocalcinbiology.proteinAlkaline phosphataseBone marrow0210 nano-technologymedicine.drugJournal of Biomedical Materials Research Part A
researchProduct

Intraosseous monitoring of drilling in lumbar vertebrae by ultrasound: An experimental feasibility study.

2016

The rationale for this project is to evaluate the efficiency of a novel sonographic method for measurements of interosseous distances. The method utilizes a propagating ultrasonic beam through aqueous milieu which is directed as a jet into a drilled tract. We used a plastic model of human L5 vertebra and ex vivo specimen of L5 porcine vertebra and generated 2 mm in diameter tracts in vertebral pedicles. The tracts were created in the "desired" central direction and in the "wrong" medial and lateral directions. The drilled tracts and the residual, up to opposite cortex, distances were measured sonographically and mechanically and compared statistically. We show that "true" mechanical measure…

Models AnatomicVertebraeSwinelcsh:MedicineReflectionDistance Measurement01 natural sciences0302 clinical medicineMathematical and Statistical TechniquesBone DensityMedicine and Health SciencesOrthopedic Procedureslcsh:Science010301 acousticsMusculoskeletal SystemMeasurementMultidisciplinaryUltrasonic beamLumbar VertebraePhysicsUltrasoundClassical MechanicsAnatomymedicine.anatomical_structureConnective TissuePhysical SciencesEngineering and TechnologyRegression AnalysisTomographyAnatomyPlasticsGeologyStatistics (Mathematics)Research Articlemusculoskeletal diseasesMaterials ScienceMaterial PropertiesSurgical and Invasive Medical ProceduresLumbar vertebraeLinear Regression AnalysisResearch and Analysis Methods03 medical and health sciencesLumbar0103 physical sciencesmedicineAnimalsHumansL5 VertebraStatistical MethodsBoneUltrasonography Interventionalbusiness.industrylcsh:RDrillingBiology and Life SciencesSpineVertebraBiological TissueSignal ProcessingLinear ModelsFeasibility Studieslcsh:QbusinessTomography X-Ray Computed030217 neurology & neurosurgeryMathematicsPloS one
researchProduct

Reaction of 3-Amino-1,2,4-Triazole with Diethyl Phosphite and Triethyl Orthoformate: Acid-Base Properties and Antiosteoporotic Activities of the Prod…

2017

The reaction of diethyl phosphite with triethyl orthoformate and a primary amine followed by hydrolysis is presented, and the reaction was suitable for the preparation of (aminomethylene)bisphosphonates. 3-Amino-1,2,4-triazole was chosen as an interesting substrate for this reaction because it possesses multiple groups that can serve as the amino component in the reaction-namely, the side-chain and triazole amines. This substrate readily forms 1,2,4-triazolyl-3-yl-aminomethylenebisphosphonic acid (compound 1) as a major product, along with N-ethylated bisphosphonates as side products. The in vitro antiproliferative effects of the synthesized aminomethylenebisphosphonic acids against J774E m…

Models Molecularorganophosphorus chemistryPhosphitesBase (chemistry)FormatesTriazoleMolecular ConformationPharmaceutical ScienceOsteoclastsApoptosis010402 general chemistry01 natural sciencesAnalytical Chemistrylcsh:QD241-441chemistry.chemical_compoundHydrolysisMicelcsh:Organic chemistryCell Line TumorDrug DiscoveryOrganic chemistryAnimals3-Amino-124-triazolePhysical and Theoretical Chemistrycrystallographychemistry.chemical_classificationBone Density Conservation AgentsDiphosphonates010405 organic chemistryChemistryCommunicationOrganic ChemistrySubstrate (chemistry)Triazolesthree-component reactionTriethyl orthoformateUV-Vis spectroscopyMagnetic Resonance Imaging0104 chemical sciencesP-containing drugstriazoleChemistry (miscellaneous)potentiometryaminomethylenebisphosponatesMolecular Medicineanti-proliferative activityAmine gas treatingpH-titrationbisphosphonic acidsMolecules (Basel, Switzerland)
researchProduct

Efficacy of platelet-rich plasma applied to post-extraction retained lower third molar alveoli. A systematic review

2013

Dental retentions have a high prevalence among the general population and their removal can involve multiple complications. The use of platelet rich plasma has been proposed in an attempt to avoid these complications, as it contains high growth factors and stimulates diverse biological functions that facilitate the healing of soft and hard tissues. Objectives: To evaluate the available scientific evidence related to the application of platelet-rich plasma in the post-extraction alveoli of a retained lower third molars. Material and Methods: A systematic review of published literature registered in the Medline, EMBASE, Cochrane and NIH databases. The following categories were included: human…

MolarBone densityPopulationDentistryOdontologíalaw.inventionPostoperative ComplicationsRandomized controlled triallawmedicineHumansPlateletTooth SocketeducationGeneral DentistryDental alveoluseducation.field_of_studyPlatelet-Rich Plasmabusiness.industryResearchmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludOtorhinolaryngologyPlatelet-rich plasmaUNESCO::CIENCIAS MÉDICASTooth ExtractionMolar ThirdSurgeryOral SurgeryOsteitisbusiness
researchProduct

Effects of zoledronic acid and dexamethasone on early phases of socket healing after tooth extraction in rats : a preliminary macroscopic and microsc…

2018

Background The exact pathogenesis of medication-related osteonecrosis of the jaw (MRONJ) is still unknown. The aim of this paper was to investigate the effects of zoledronic acid and dexamethasone on the early phases of socket healing in rats subjected to tooth extractions. Material and Methods Thirty male Sprague-Dawley rats were divided into 2 groups: pharmacologically treated group (T, n=20) and non-pharmacologically treated group (C, n=10). T group rats received 0.1 mg/Kg of zoledronic acid (ZOL) and 1 mg/Kg of dexamethasone (DEX) three times a week for 10 consecutive weeks. C group rats were infused with vehicle. After 9 weeks from the first infusion, first maxillary molars were extrac…

MolarMalemedicine.medical_specialtyConnective tissueZoledronic AcidDexamethasoneBone remodelingRats Sprague-Dawley03 medical and health sciences0302 clinical medicineOsteoclastInternal medicinemedicineAnimalsHumansTooth SocketGeneral DentistryDexamethasoneDental alveolusOral Medicine and PathologyBone Density Conservation AgentsDiphosphonatesbusiness.industryResearchOsteonecrosis030206 dentistrymedicine.disease:CIENCIAS MÉDICAS [UNESCO]Ratsmedicine.anatomical_structureZoledronic acidEndocrinologyOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASTooth ExtractionSurgerybusinessOsteonecrosis of the jawmedicine.drug
researchProduct

Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey

2013

BackgroundBone metastasis represents an increasing clinical problem in advanced gastric cancer (GC) as disease-related survival improves. In literature, few data on the natural history of bone disease in GC are available.Patients and methodsData on clinicopathology, skeletal outcomes, skeletal-related events (SREs), and bone-directed therapies for 208 deceased GC patients with evidence of bone metastasis were statistically analyzed.ResultsMedian time to bone metastasis was 8 months (CI 95%, 6.125-9.875 months) considering all included patients. Median number of SREs/patient was one. Less than half of the patients (31%) experienced at least one and only 4 and 2% experienced at least two and …

OncologyAdultMalemedicine.medical_specialtyPathologyBone diseaseSettore MED/06 - Oncologia Medicamedicine.medical_treatmentScienceBone NeoplasmsMetastasisgastric cancer; bone metastasisStomach NeoplasmsInternal medicinemedicineHumansskeletal disease advanced hepatocellular carcinomaskeletal-related events bisphosphonateAdult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Patient Outcome Assessment; Population Surveillance; Prognosis; Retrospective Studies; Stomach NeoplasmsNeoplasm Metastasisbone metastasisAgedRetrospective StudiesMultidisciplinaryBone Density Conservation AgentsDiphosphonatesbusiness.industrygastric cancerQRBone metastasisCancerBone fractureMiddle Agedmedicine.diseasePrognosisRadiation therapyPatient Outcome AssessmentBone Density Conservation AgentsZoledronic acidPopulation SurveillanceMedicineFemalebusinessmedicine.drugResearch Article
researchProduct

Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab) - Review.

2015

Background Denosumab, an anti-resorptive agent, IgG2 monoclonal antibody for human Receptor activator of nuclear factor-kappa B ligand (RANKL), has been related to the occurrence of osteonecrosis of the jaws. Thus, the aim of this study was to review the literature from clinical case reports, regarding the type of patient and the therapeutic approach used for osteonecrosis of the jaws induced by chronic use of Denosumab. Material and Methods For this, a literature review was performed on PubMed, Medline and Cochrane databases, using the keywords “Denosumab” “anti-RANK ligand” and “Osteonecrosis of jaw”. To be included, articles should be a report or a serie of clinical cases, describing pat…

OncologyMalemedicine.medical_specialtyOsteoporosisOdontologíaReview03 medical and health sciencesTherapeutic approachProstate cancer0302 clinical medicineDiabetes mellitusInternal medicinemedicineHumansGeneral DentistryAgedBisphosphonate-associated osteonecrosis of the jawOral Medicine and PathologybiologyBone Density Conservation AgentsDiphosphonatesbusiness.industryRANK LigandNF-kappa BOsteonecrosis030206 dentistryMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la saludSurgeryDenosumabOtorhinolaryngologyRANKL030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASbiology.proteinSurgeryBisphosphonate-Associated Osteonecrosis of the JawFemaleDenosumabbusinessOsteonecrosis of the jawmedicine.drugMedicina oral, patologia oral y cirugia bucal
researchProduct

Medication-related osteonecrosis of the jaw in a cancer patient receiving lenvatinib.

2018

Medication-related osteonecrosis of the jaw (MRONJ) is an adverse drug reaction that affects the mandible and maxilla of patients exposed to bone-targeting agents such as anti-resorptive and anti-angiogenic agents. Several MRONJ cases have been reported after dental extractions in patients under treatment with anti-angiogenic agents, including receptor activator of nuclear factor κB ligand (RANKL) inhibitor, anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody, mammalian target of rapamycin (mTOR) inhibitors, and tyrosine kinase inhibitors (TKIs). The aim of this article was to describe an original case of lenvatinib-related osteonecrosis of the jaw in a patient affected …

OncologyMalemedicine.medical_specialtymedicine.medical_treatmentlenvatinibMRONJ03 medical and health scienceschemistry.chemical_compound0302 clinical medicineSettore MED/28 - Malattie OdontostomatologicheInternal medicinemedicineAnimalsHumansThyroid cancerbiologyBone Density Conservation AgentsDiphosphonatesbusiness.industryPhenylurea CompoundsOsteonecrosis030206 dentistryMiddle Agedmedicine.diseaseosteonecrosis of the jawOtorhinolaryngologyDental extractionchemistryRANKL030220 oncology & carcinogenesisConcomitantbiology.proteinQuinolinesSurgeryBisphosphonate-Associated Osteonecrosis of the Jawdental extractionOral SurgerybusinessLenvatinibOsteonecrosis of the jawTyrosine kinaseAdverse drug reactionInternational journal of oral and maxillofacial surgery
researchProduct

Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study.

2012

ABSTRACT Background Data are limited regarding bone metastases from colorectal cancer (CRC). The objective of this study was to survey the natural history of bone metastasis in CRC. Patients and methods This retrospective, multicenter, observational study of 264 patients with CRC involving bone examined cancer treatments, bone metastases characteristics, skeletal-related event (SRE) type and frequency, zoledronic acid therapy, and disease outcomes. Results Most patients with bone metastases had pathologic T3/4 disease at CRC diagnosis. The spine was the most common site involved (65%), followed by hip/pelvis (34%), long bones (26%), and other sites (17%). Median time from CRC diagnosis to b…

Oncologymedicine.medical_specialtyBone Density Conservation AgentSettore MED/06 - Oncologia MedicaColorectal cancerBone NeoplasmsColorectal NeoplasmBone Neoplasmdrug therapy/pathologyZoledronic AcidInternal medicinemedicineHumansImidazolePelvisRetrospective Studiesdrug therapy/secondarybone metastases colorectal cancer zoledronic acidBone Density Conservation AgentsDiphosphonatesbusiness.industryImidazolesBone metastasisCancerRetrospective cohort studyHematologymedicine.diseaseNatural historyBone Density Conservation AgentsZoledronic acidmedicine.anatomical_structureDiphosphonateOncologytherapeutic useBone Density Conservation Agents; therapeutic use; Bone Neoplasms; drug therapy/secondary; Colorectal Neoplasms; drug therapy/pathology; Diphosphonates; Humans; Imidazoles; Retrospective StudiesbusinessColorectal NeoplasmsHumanmedicine.drug
researchProduct

Osteonecrosis of the jaw (ONJ) risk in breast cancer patients after zoledronic acid treatment

2010

The importance of adoption of recommendations for ONJ prevention strategy will notably grow for zoledronic acid in the next future, in view of possible further enlargement of its indications (even with different timing and schedules) in breast cancer patients without bone metastases (such as in adjuvant and neo-adjuvant settings, and in hormonotherapy-induced osteopenia

Oncologymedicine.medical_specialtyBreast Neoplasmszoledronic acidBreast cancerSettore MED/28 - Malattie OdontostomatologicheInternal medicinemedicineHumansBone Density Conservation AgentsDiphosphonatesOsteonecrosis of the jawbusiness.industryImidazolesOsteonecrosisGeneral Medicinemedicine.diseaseosteonecrosis jawsZoledronic acidJawbreast cancer patientsFemaleSurgerybusinessOsteonecrosis of the jawmedicine.drugThe Breast
researchProduct